The Latest "Buzz on the Street" Show: Featuring Pressure Biosciences (OTCQB: PBIO) Biotech Research | Financial Buzz

The Latest “Buzz on the Street” Show: Featuring Pressure Biosciences (OTCQB: PBIO) Biotech Research’s latest Buzz on the Street Show: Featuring Our Corporate News Recap on Pressure BioSciences Names the Vogel Laboratory at New York University’s Center for Genomics and Systems Biology a Center of Excellence”

Pressure BioSciences, Inc. (OTCQB: PBIO) announced the establishment of a Center of Excellence at Dr. Christine Vogel’s laboratory at New York University’s Center for Genomics and Systems Biology.

Pressure BioSciences, Inc. is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. Our products are based on the unique properties of both constant and alternating hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions.

Diseases are commonplace around the world, especially in regions that don’t have access to adequate healthcare. In such underdeveloped regions, diseases such as AIDS, malaria, and tuberculosis ravage countries and their inhabitants. According to the World Health Organization, in third world countries, people face tens of thousands of deaths daily due to untreated conditions and many of these diseases occur through environmental impacts or purely through hereditary conditions. However, even in developed countries, cases of cancer, heart disease, respiratory disease, and diabetes are growing. The alarming rates have also prompted biotechnology companies to conduct research and development of new treatments in order to effectively combat the growing incidences. According to data compiled by Polaris Market Research, the global biotechnology market was valued at USD 390.1 Billion in 2017 and is projected to reach USD 741.7 Billion by 2026. Furthermore, the market is expected to witness a CAGR of 7.7% during the forecast period from 2019 to 2026. Specifically, the market is expected to be propelled by the growing number of R&D expenditures and the outsourcing activities by both private and government bodies. Moreover, the rising number of future conferences and workshops is also expected to bolster the industry’s growth. 

In 2017, biopharmacy applications accounted for approximately 60% of the overall biotechnology market share. The sector itself is expected to continually flourish due to the increased use of bio-recombinant proteins in many of the medications used to treat ailments, as biopharma companies are now focusing on improving customized medicine to further enhance patient recovery. The major difference between biopharmaceutical and pharmaceutical companies is that the former focus on a compound of chemical synthesis which is developed in academic and industrial laboratories, according to Morgan Mckinley. These companies are much more focused on research in order to develop effective treatments. Overall, the growing number of life-threatening medical conditions will further accelerate the overall biotechnology industry’s growth. “Biotechnology is a huge part of our everyday lives, from the clothes we wear, the food we eat, the medicine we use to keep us healthy and even the fuel we use to take us around. Biotech already plays, and will continue to play, an invaluable role in meeting our needs. No other industry is better placed to enhance quality of life and respond to society’s ‘Grand Challenges’ of tackling an ageing and ever-increasing population, healthcare and affordability, resource efficiency, food security, climate change and energy shortages,” said Jason Johal, Manager at CK Sciences.

For more information, please visit: Pressure Biosciences, Inc.

For more corporate news on Pressure Biosciences Inc., check out the Buzz on the Street

About Buzz on the Street: One of’s latest corporate and financial news shows, covering the latest trending stock market news. Buzz on the Street looks to become a leader in corporate video news dissemination. Buzz on the Street is 100% original content, brought to you by Financial Buzz Media.

Sponsored Content Release. Click for Full Disclosure

  • Sponsored Content Release, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, creates 100% unique original content. also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

    Please Note: is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on (the ‘Site’) is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content),, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. receives fees for producing and presenting high quality and sophisticated content on along with other financial news PR media services. does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For pressure biosciences, inc, financial and corporate news dissemination, has been compensated five thousand dollars by the company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. has signed a one-year agreement with pressure biosciences inc. for fifty thousand restricted common shares for continued financial and corporate news dissemination. will always disclose any compensation in securities or cash payments for financial news PR advertising. does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security., members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: